智翔金泰：关于GR1802注射液启动过敏性鼻炎适应症Ⅲ期临床试验的公告

Core Viewpoint - The company Zhixiang Jintai announced the initiation of a Phase III clinical trial for GR1802 injection in patients with seasonal allergic rhinitis, following a successful communication with the National Medical Products Administration (NMPA) [1] Group 1 - The clinical trial is randomized, double-blind, placebo-controlled, and multi-center [1] - The trial aims to evaluate the efficacy and safety of GR1802 injection combined with background therapy [1] - The meeting with the Center for Drug Evaluation (CDE) marked the completion of the end of Phase II and the start of Phase III clinical trials [1]